Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

Medicare beneficiaries face new restrictions on popular weight loss medication coverage amid broader prescription drug policy ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Wegovy isn’t typically covered by insurance — that applies to both private insurance and Medicare ... But even with coverage, your Wegovy out-of-pocket costs may still include a copay or ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Novo Nordisk will sell a one-month supply of Wegovy for $199 through June 30 ... administration rejected a Biden proposal to expand Medicare coverage of the weight-loss medications.